Biomarkers for iap inhibitor therapy
AssigneeNovartis AG
InventorsDale Porter, John Scott Cameron, Caroline Emery, Douglas Robinson, Kavitha Venkatesan, Li Wang
Life of this patent
Estimating the term…
Abstract
A method of selecting a subject having cancer for treatment with an IAP inhibitor.
Claims13
A method of analyzing a biological sample of a subject with cancer, comprising determining a level of mRNA expression of biomarkers TNF and RIPK1 and one or more of the following biomarkers CXLC10, CCL5, NFKBIA, HERC5, CDYL, STK39 and MAPK14 in the biological sample taken from the subject using RT-PCR, wherein the level of expression of the biomarkers in comparison to a control indicates that the subject has an increased likelihood of response to an Inhibitor of Apoptosis Protein (IAP) inhibitor.
(canceled)
A method of treating a subject having cancer, comprising:
- assaying a biological sample from the subject for a level of expression of biomarkers TNF and RIPK1 and one or more of the following biomarkers CXLC10, CCL5, NFKBIA, HERC5, CDYL, STK39 and MAPK14 in the biological sample taken from the subject;
- and
- administering (S)—N—((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide to the subject on the basis that the subject's sample has been determined to have a level of biomarker expression indicative that the subject has an increased likelihood of response to (S)—N—((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide.
A method of treating a subject having cancer with an inhibitor of Apoptosis Protein (IAP) inhibitor, comprising administering an IAP inhibitor to the subject as a result of the subject having been determined to have a level of mRNA expression of TNF, RIPK1 and STK39 which is indicative that the subject has an increased likelihood of response to an IAP inhibitor.
(canceled)
A kit comprising a plurality of agents for determining the level of mRNA expression of biomarkers TNF and RIPK1 and one or more of the following biomarkers CXLC10, CCL5, NFKBIA, HERC5, CDYL, STK39 and MAPK14 in a sample and instructions for use.
Dependencies are inferred from the claim text.